David A. Siegel Gt Biopharma, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$1.64 - $3.11 $13,612 - $25,813
-8,300 Reduced 44.86%
10,200 $30,000
Q1 2022

May 16, 2022
SELL
$2.6 - $3.3 $263,640 - $334,620
-101,400 Reduced 84.57%
18,500 $53,000
Q4 2021

Feb 14, 2022
BUY
$3.05 - $7.08 $209,840 - $487,104
68,800 Added 134.64%
119,900 $366,000
Q3 2021

Nov 15, 2021
BUY
$6.68 - $15.26 $241,816 - $552,412
36,200 Added 242.95%
51,100 $344,000
Q2 2021

Aug 16, 2021
BUY
$7.19 - $18.96 $107,131 - $282,504
14,900 New
14,900 $231,000

Others Institutions Holding GTBP

# of Institutions
4
Shares Held
564
Call Options Held
0
Put Options Held
0
View Full List

About GT Biopharma, Inc.

GTBP Quotes by TradingView
  • Ticker GTBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,557,700
  • Market Cap $81.7M
  • Description
  • GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...
More about GTBP
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email